Boehringer Ingelheim and Microsoft announced an early-stage collaboration to develop AI-powered “digital patient twins” for clinical trials. The goal is to simulate disease progression and treatment response and potentially support synthetic or hybrid control strategies, with an emphasis on improving trial design and evidence generation efficiency. Boehringer said the work will be exploratory and contingent on robust scientific validation and applicable regulatory approvals. The announcement comes amid broader trial-focused dealmaking between drug companies and AI providers, and follows the HHS SURPASS program, which uses digital twin approaches for trial design feasibility. If validated, the approach could reduce reliance on placebo-only controls and shorten parts of development timelines—though the regulatory bar for substituting or supplementing control arms remains high.